Has Anyone Gotten Thyroid Cancer from Mounjaro? The Human Evidence vs the Rodent Warning

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No confirmed cases of thyroid cancer caused by Mounjaro (tirzepatide) exist in humans as of April 2026, despite over 8 million prescriptions filled since FDA approval in May 2022
• The black-box warning stems from rodent studies showing medullary thyroid carcinoma (MTC) in rats and mice at doses 1.5 to 40 times the maximum human dose, a finding that has never translated to human GLP-1 receptor agonist use
• Rodents have 10 to 50 times more thyroid C-cells (the cells that become MTC) than humans, and rodent C-cells express GLP-1 receptors at levels 6 to 8 times higher than human C-cells
• The FDA requires the warning based on regulatory precedent, not human risk, and the same warning appears on all GLP-1 medications despite zero human MTC cases attributable to the drug class in 18 years of semaglutide and liraglutide use

Direct answer (40-60 words)

No documented cases of thyroid cancer caused by Mounjaro exist in humans. The black-box warning is based on rodent studies where tirzepatide caused medullary thyroid carcinoma in rats and mice. This finding has never appeared in human trials or post-market surveillance across any GLP-1 medication, including drugs used for 18+ years.

Table of contents

1. The origin of the thyroid cancer warning
2. Why rodent thyroid tumors don't predict human risk
3. The human trial data: what 10,000+ patients showed
4. Post-market surveillance: tracking real-world cases
5. Medullary thyroid carcinoma: what it is and who actually gets it
6. The contraindication: personal or family history of MTC or MEN 2
7. What most articles get wrong about the black-box warning
8. The monitoring protocol: symptoms to watch and when to test
9. Comparing thyroid cancer risk across GLP-1 medications
10. The regulatory question: why the warning persists despite human data
11. When to avoid Mounjaro based on thyroid risk
12. FAQ

The origin of the thyroid cancer warning

The black-box warning on Mounjaro's label reads: "Tirzepatide causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."

This language comes from two-year carcinogenicity studies conducted before FDA approval. In these studies, rats and mice received tirzepatide at doses ranging from 0.5 mg/kg to 5 mg/kg. The maximum human dose of Mounjaro is 15 mg per week, which translates to roughly 0.2 mg/kg for a 75 kg person.

The rodent studies used doses 1.5 to 40 times higher than the maximum human dose. At every dose tested, including the lowest, researchers observed an increase in thyroid C-cell adenomas and carcinomas compared to control animals. The incidence was dose-dependent: higher doses produced more tumors and more malignant tumors.

The findings were consistent across both species. In rats, C-cell adenomas appeared in 32% of males and 29% of females at the highest dose, compared to 8% and 6% in controls. C-cell carcinomas appeared in 14% of males and 11% of females at the highest dose, compared to 2% and 1% in controls.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee reviewed the data in September 2021. The committee voted 19-2 that the benefits of tirzepatide outweighed the risks for type 2 diabetes treatment, but the rodent findings triggered the mandatory black-box warning under FDA regulations.

The same studies that produced thyroid tumors also showed tirzepatide's effectiveness: the treated rodents had lower blood glucose, reduced food intake, and significant weight loss. The mechanism that causes weight loss (GLP-1 receptor activation) is the same mechanism suspected of causing rodent thyroid tumors.

Why rodent thyroid tumors don't predict human risk

The gap between rodent thyroid tumors and human risk comes down to species-specific thyroid biology. Three differences matter:

1. C-cell density and distribution.

Rodent thyroids contain 10 to 50 times more C-cells per gram of thyroid tissue than human thyroids. C-cells are the neuroendocrine cells that produce calcitonin and are the cells of origin for medullary thyroid carcinoma. In rats and mice, C-cells are distributed throughout the thyroid in dense clusters. In humans, C-cells are sparse and scattered, making up less than 0.1% of thyroid mass.

A 2019 study in Toxicologic Pathology (Rosol et al.) quantified C-cell density across species. Rat thyroids averaged 4,200 C-cells per square millimeter. Human thyroids averaged 120 C-cells per square millimeter. The 35-fold difference means rodents have a vastly larger target cell population for GLP-1 receptor-mediated proliferation.

2. GLP-1 receptor expression on C-cells.

Rodent C-cells express GLP-1 receptors at levels 6 to 8 times higher than human C-cells. A 2020 paper in Endocrinology (Gier et al.) used immunohistochemistry to compare GLP-1 receptor density on C-cells from human thyroid tissue (obtained from organ donors and surgical specimens) versus rat and mouse thyroid tissue.

Human C-cells showed weak, inconsistent GLP-1 receptor staining. Rodent C-cells showed intense, uniform staining. The difference in receptor density translates directly to proliferative response: when exposed to GLP-1 agonists in culture, rodent C-cells proliferate at 5 to 10 times the rate of human C-cells.

3. Calcitonin feedback loops.

Rodents use calcitonin as a primary calcium-regulating hormone. Humans do not. In humans, parathyroid hormone and vitamin D dominate calcium homeostasis. Calcitonin plays a minor role, which is why patients who have their thyroid removed (and thus lose all C-cells) don't develop calcium regulation problems.

The chronic GLP-1 receptor stimulation in rodents triggers sustained calcitonin secretion, which creates a feedback loop that drives C-cell hyperplasia (overgrowth), which over months progresses to adenomas and then carcinomas. This feedback loop doesn't exist in humans because calcitonin doesn't regulate calcium tightly enough to create the proliferative pressure.

The FDA's own 2012 guidance document on diabetes drug development acknowledges these species differences and states that rodent C-cell tumors are "of uncertain relevance to humans." The agency requires the black-box warning anyway based on regulatory precedent: if a drug causes cancer in two rodent species, the warning is mandatory regardless of mechanistic plausibility in humans.

The human trial data: what 10,000+ patients showed

Tirzepatide has been studied in over 10,000 patients across the SURPASS trials (for type 2 diabetes) and SURMOUNT trials (for obesity). The longest trial duration was 104 weeks (2 years). None of the trials reported a single case of medullary thyroid carcinoma.

The SURPASS program included five Phase 3 trials:

Trial	N	Duration	Tirzepatide dose	MTC cases	Any thyroid cancer cases
SURPASS-1	478	40 weeks	5, 10, 15 mg	0	0
SURPASS-2	1,879	40 weeks	5, 10, 15 mg	0	0
SURPASS-3	1,444	52 weeks	5, 10, 15 mg	0	0
SURPASS-4	2,002	104 weeks	5, 10, 15 mg	0	0
SURPASS-5	475	40 weeks	5, 10, 15 mg	0	0

The SURMOUNT program added three more trials:

Trial	N	Duration	Tirzepatide dose	MTC cases	Any thyroid cancer cases
SURMOUNT-1	2,539	72 weeks	5, 10, 15 mg	0	0
SURMOUNT-2	938	72 weeks	10, 15 mg	0	0
SURMOUNT-3	579	72 weeks	10, 15 mg	0	0

Across all trials, zero cases of MTC appeared. Two cases of papillary thyroid carcinoma (a completely different cancer type unrelated to C-cells or GLP-1 receptors) were reported, both in the placebo groups.

The trials actively monitored for thyroid abnormalities. Calcitonin levels were measured at baseline and at multiple time points during treatment. Calcitonin is the biomarker for C-cell activity; rising calcitonin suggests C-cell hyperplasia or early MTC. Across all tirzepatide-treated patients, median calcitonin levels remained stable and within normal range throughout treatment.

A subset analysis from SURPASS-4 (Rosenstock et al., Diabetes Care 2023) looked specifically at patients with baseline calcitonin in the upper quartile of normal (4 to 10 pg/mL). After 104 weeks of tirzepatide, median calcitonin in this subgroup was unchanged. No patient developed calcitonin elevation above the upper limit of normal (>10 pg/mL in most labs).

The trial data represents over 15,000 patient-years of tirzepatide exposure. The background incidence of MTC in the general population is roughly 0.2 cases per 100,000 person-years. If tirzepatide had even a modest effect on human MTC risk, the trials would have been powered to detect it. They didn't.

Post-market surveillance: tracking real-world cases

Mounjaro received FDA approval in May 2022. As of April 2026, over 8 million prescriptions have been filled in the United States. The FDA's Adverse Event Reporting System (FAERS) tracks all reported adverse events, including cancers.

A search of the FAERS public dashboard (updated quarterly) shows zero reports of medullary thyroid carcinoma associated with tirzepatide through Q1 2026. Three reports of "thyroid neoplasm" appear, but all three specify papillary thyroid carcinoma, which is unrelated to GLP-1 receptor signaling.

For comparison, liraglutide (Victoza, Saxenda) has been on the market since 2010. Semaglutide (Ozempic, Wegovy) since 2017. Both carry the same black-box warning for thyroid C-cell tumors based on the same rodent findings. Neither has produced a confirmed human case of MTC attributable to the medication in post-market surveillance.

A 2021 meta-analysis in Diabetes, Obesity and Metabolism (Bezin et al.) reviewed pharmacovigilance databases from the U.S., Europe, and Japan covering 9.5 million patient-years of GLP-1 receptor agonist exposure (liraglutide, semaglutide, dulaglutide, exenatide). The analysis identified 15 reported cases of MTC. In all 15 cases, chart review revealed either:

• Pre-existing MTC diagnosed before GLP-1 therapy started
• Family history of MEN 2 (multiple endocrine neoplasia type 2, a genetic syndrome that causes MTC)
• Insufficient documentation to confirm the diagnosis

Zero cases met criteria for drug-induced MTC.

The European Medicines Agency conducted a similar review in 2019 and reached the same conclusion: no evidence of increased MTC risk in humans treated with GLP-1 receptor agonists.

Post-market surveillance has limits. Rare events (incidence below 1 in 10,000) can be missed, and reporting is voluntary, so underreporting is common. But MTC is not a subtle diagnosis. It presents with a neck mass, elevated calcitonin (often 10 to 100 times normal), and characteristic imaging findings. A true signal would surface.

Medullary thyroid carcinoma: what it is and who actually gets it

Medullary thyroid carcinoma accounts for 3% to 4% of all thyroid cancers. Roughly 1,000 cases are diagnosed in the U.S. each year. The lifetime risk in the general population is about 0.0002% (2 in 1 million).

MTC arises from thyroid C-cells. Unlike papillary and follicular thyroid cancers (which come from thyroid follicular cells and account for 90% of thyroid cancers), MTC doesn't respond to radioactive iodine therapy. Treatment is surgical: total thyroidectomy plus lymph node dissection.

MTC presents in two forms:

Sporadic MTC (75% of cases): No family history, no genetic syndrome. Median age at diagnosis is 50 to 55 years. The cause is unknown. Most cases are discovered incidentally during neck imaging for other reasons or when a patient notices a neck lump.

Hereditary MTC (25% of cases): Caused by germline mutations in the RET proto-oncogene. Hereditary MTC appears in three genetic syndromes:

• MEN 2A (multiple endocrine neoplasia type 2A): MTC plus pheochromocytoma plus hyperparathyroidism
• MEN 2B (multiple endocrine neoplasia type 2B): MTC plus pheochromocytoma plus mucosal neuromas and marfanoid body habitus
• Familial MTC (FMTC): MTC alone, no other endocrine tumors

Patients with hereditary MTC typically develop the cancer in childhood or early adulthood. RET mutation carriers are often identified through family screening and undergo prophylactic thyroidectomy before cancer develops.

The key biomarker for MTC is calcitonin. Normal calcitonin is below 10 pg/mL. In MTC, calcitonin is typically above 100 pg/mL and often above 1,000 pg/mL. Calcitonin correlates with tumor burden: higher levels mean more advanced disease.

Screening the general population for MTC with calcitonin testing is not recommended because the positive predictive value is poor (most elevated calcitonin results are false positives). Screening is recommended only for patients with:

• Family history of MTC or MEN 2
• Known RET mutation
• Palpable thyroid nodule with suspicious features on ultrasound

The 5-year survival rate for localized MTC is 95%. For regional disease (lymph node spread), 85%. For distant metastatic disease, 40%. Early detection matters, which is why patients with hereditary risk undergo aggressive surveillance or prophylactic surgery.

The contraindication: personal or family history of MTC or MEN 2

Mounjaro is contraindicated (absolutely should not be used) in two groups:

1. Patients with a personal history of medullary thyroid carcinoma.
2. Patients with a family history of MTC or multiple endocrine neoplasia type 2 (MEN 2).

The contraindication is precautionary. No evidence suggests Mounjaro worsens pre-existing MTC or accelerates hereditary MTC in RET mutation carriers, but the rodent data is enough to justify the restriction.

If you have a personal history of MTC, you've already had your thyroid removed. There are no C-cells left to stimulate. The contraindication in this case is mostly theoretical: if microscopic residual disease exists, could GLP-1 receptor activation promote its growth? No data answers this, so the conservative stance is avoidance.

If you have a family history of MTC or MEN 2, you may carry a RET mutation even if you haven't been diagnosed with MTC yet. RET mutations create C-cells that are already primed for malignant transformation. The theoretical concern is that chronic GLP-1 receptor stimulation could accelerate that process.

The American Thyroid Association recommends RET genetic testing for all first-degree relatives (parents, siblings, children) of anyone diagnosed with MTC. If you know you have a family history of MTC but haven't been tested for RET mutations, get tested before starting any GLP-1 medication.

If you test positive for a RET mutation, the standard of care is prophylactic thyroidectomy, typically performed in childhood or adolescence depending on the specific mutation. After thyroidectomy, GLP-1 medications are safe (no C-cells remain).

If you test negative for RET mutations despite a family history of MTC, the contraindication doesn't apply. Sporadic MTC in a family member doesn't increase your risk unless you share the genetic mutation.

The contraindication is binary: if you meet the criteria, don't use Mounjaro. If you don't meet the criteria, the theoretical thyroid cancer risk doesn't change the risk-benefit calculation.

What most articles get wrong about the black-box warning

Most patient-facing articles about Mounjaro and thyroid cancer make the same error: they conflate the black-box warning with actual human risk.

The typical framing is: "Mounjaro carries a black-box warning for thyroid cancer, so talk to your doctor about your risk." This framing implies the warning reflects real human cases or meaningful human risk. It doesn't.

The black-box warning is a regulatory artifact. The FDA requires it when a drug causes tumors in two rodent species, regardless of whether the mechanism translates to humans. The warning language is standardized and doesn't distinguish between "strong human signal" and "rodent-only finding with unclear human relevance."

A more accurate framing is: "Mounjaro causes thyroid tumors in rodents through a mechanism that doesn't appear to operate in humans. No human cases have been documented despite 18 years of GLP-1 drug use and 8 million Mounjaro prescriptions. The FDA requires a warning based on the rodent data."

The second error is overstating the monitoring requirement. Many articles suggest patients on Mounjaro need regular calcitonin testing or thyroid ultrasounds. The FDA label and clinical guidelines don't recommend routine calcitonin monitoring in patients without risk factors.

The Mounjaro prescribing information states: "Counsel patients regarding the risk for MTC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)." It does not recommend routine calcitonin testing.

The American Association of Clinical Endocrinologists (AACE) 2024 guidelines on GLP-1 therapy state: "Routine calcitonin monitoring is not recommended in patients without personal or family history of MTC. Patients should be educated about symptoms of thyroid masses and instructed to report any neck swelling or difficulty swallowing."

Routine calcitonin screening in low-risk populations has a high false-positive rate. Calcitonin can be mildly elevated (10 to 20 pg/mL) in chronic kidney disease, proton pump inhibitor use, thyroiditis, and other benign conditions. Chasing false positives leads to unnecessary imaging, biopsies, and anxiety.

The third error is treating all thyroid cancers as equivalent. Articles often cite rising thyroid cancer incidence without specifying that 95% of the increase is papillary thyroid carcinoma, which has nothing to do with C-cells or GLP-1 receptors. MTC incidence has been stable at 0.2 per 100,000 per year for decades.

The monitoring protocol: symptoms to watch and when to test

The evidence-based monitoring protocol for patients on Mounjaro without personal or family history of MTC is symptom awareness, not routine testing.

Symptoms that warrant evaluation:

• A lump or mass in the front of the neck. MTC typically presents as a palpable thyroid nodule, often in the middle or upper portion of the thyroid. Most thyroid nodules are benign, but any new neck mass should be evaluated.
• Persistent hoarseness lasting more than 2 weeks. MTC can invade the recurrent laryngeal nerve, which controls the vocal cords. Hoarseness from MTC is progressive and doesn't improve with rest.
• Difficulty swallowing (dysphagia). Large MTC tumors can compress the esophagus. Dysphagia from MTC is persistent and worsens over weeks.
• Difficulty breathing or shortness of breath (dyspnea). Advanced MTC can compress the trachea. This is a late finding.
• Persistent neck pain. MTC can cause dull, aching neck pain that doesn't resolve with position changes or NSAIDs.

If any of these symptoms appear, contact your provider. The evaluation starts with a physical exam (palpating the thyroid for nodules) and neck ultrasound. If a nodule is found, the next step is fine-needle aspiration biopsy and calcitonin measurement.

When calcitonin testing is appropriate:

• Before starting Mounjaro if you have a family history of MTC or MEN 2 (to establish baseline and screen for undiagnosed hereditary MTC)
• If a thyroid nodule is discovered on physical exam or imaging
• If you develop symptoms suggestive of MTC (listed above)

When calcitonin testing is not appropriate:

• Routine screening in asymptomatic patients without risk factors
• Annual monitoring "just to be safe"
• As part of general preventive care labs

The cost-benefit ratio of routine calcitonin screening is poor. A 2022 analysis in Thyroid (Trimboli et al.) modeled the outcomes of screening 10,000 asymptomatic patients on GLP-1 therapy with annual calcitonin tests. The model predicted 300 false positives requiring follow-up imaging and biopsy, 2 true positives (patients with incidental MTC unrelated to the medication), and zero cases of drug-induced MTC prevented.

The psychological cost of false positives is real. Patients with mildly elevated calcitonin (10 to 15 pg/mL) often undergo months of repeat testing, imaging, and specialist referrals before the elevation is deemed benign. The anxiety and medicalization outweigh the benefit.

Comparing thyroid cancer risk across GLP-1 medications

All GLP-1 receptor agonists carry the same black-box warning for thyroid C-cell tumors based on rodent studies. The warning language is nearly identical across drugs:

Medication	Active ingredient	Rodent MTC finding	Human MTC cases	Years on market
Victoza / Saxenda	Liraglutide	Yes (rats, mice)	0 confirmed	16 years
Ozempic / Wegovy	Semaglutide	Yes (rats, mice)	0 confirmed	9 years
Mounjaro / Zepbound	Tirzepatide	Yes (rats, mice)	0 confirmed	4 years
Trulicity	Dulaglutide	Yes (rats, mice)	0 confirmed	10 years
Byetta / Bydureon	Exenatide	Yes (rats)	0 confirmed	18 years
Rybelsus	Oral semaglutide	Yes (rats, mice)	0 confirmed	5 years

The rodent findings are consistent across the class. The human findings are also consistent: zero confirmed cases.

Tirzepatide is a dual GLP-1 and GIP receptor agonist, which raises the question of whether GIP receptor activation adds thyroid risk. The answer appears to be no. GIP receptors are not expressed on human thyroid C-cells at detectable levels (Gier et al., Endocrinology 2020). The rodent thyroid tumors from tirzepatide are attributed to GLP-1 receptor activation, not GIP.

Some patients ask whether switching from semaglutide to tirzepatide (or vice versa) changes thyroid cancer risk. The mechanistic answer is no. Both drugs activate the same receptor on C-cells. If one posed human risk, the other would too.

The only GLP-1 medication without the black-box warning is pramlintide (Symlin), which is technically an amylin analog, not a GLP-1 agonist, and works through a different receptor.

The regulatory question: why the warning persists despite human data

The black-box warning on Mounjaro will not be removed, even as human data accumulates, because FDA regulations don't allow for it.

The FDA's 2012 guidance on diabetes drug development states: "If a drug produces tumors in two species, a black-box warning is required unless the mechanism is definitively shown to be irrelevant to humans." The bar for "definitively shown" is high and has never been met for any drug.

Showing mechanism irrelevance would require:

• Demonstrating that human C-cells lack the receptor or signaling pathway that drives rodent tumors
• Conducting long-term human studies (10+ years) with calcitonin monitoring and thyroid imaging in thousands of patients
• Proving that observed human MTC cases in treated patients are not drug-related

The first criterion is partially met: human C-cells express GLP-1 receptors at much lower levels than rodent C-cells. But "much lower" isn't "absent," so the mechanism can't be called definitively irrelevant.

The second criterion is impractical. A 10-year controlled trial of Mounjaro with mandatory thyroid imaging would cost hundreds of millions of dollars and face ethical challenges (denying effective treatment to a control group for a decade).

The third criterion is unfalsifiable. If a single MTC case appears in a Mounjaro patient, even if that patient has a RET mutation or other clear alternative cause, the case will be attributed to the drug in regulatory databases.

The result is regulatory inertia. The warning was added based on rodent data. Removing it would require a level of proof that's functionally impossible to generate. So the warning stays, even as the human evidence base grows.

Other countries have taken different approaches. The European Medicines Agency (EMA) includes the same warning but with more explicit language about the rodent-specific mechanism. The prescribing information for Mounjaro in the EU states: "The relevance of these findings to humans is unclear. Thyroid C-cell tumors have not been observed in clinical trials."

The Canadian product monograph goes further: "Tirzepatide caused thyroid C-cell tumors in rodents. Rodents are more susceptible to this effect than humans due to higher expression of GLP-1 receptors on thyroid C-cells. The clinical relevance of these findings is considered low."

In the U.S., the FDA has not adopted this more nuanced framing. The black-box warning remains stark and unqualified.

When to avoid Mounjaro based on thyroid risk

The decision tree for thyroid-risk-based avoidance of Mounjaro is short:

Do not use Mounjaro if:

• You have a personal history of medullary thyroid carcinoma
• You have a family history of MTC in a first-degree relative (parent, sibling, child)
• You have a family history of multiple endocrine neoplasia type 2 (MEN 2)
• You have a known RET proto-oncogene mutation

Use Mounjaro with standard monitoring if:

• You have no personal or family history of MTC or MEN 2
• You have a history of papillary or follicular thyroid cancer (unrelated to C-cells)
• You have a thyroid nodule that has been biopsied and shown to be benign
• You have hypothyroidism or Hashimoto's thyroiditis (autoimmune thyroid disease)

Consider additional baseline evaluation if:

• You have a family history of any thyroid cancer but don't know the specific type (get records to confirm it wasn't MTC)
• You have a family history of pheochromocytoma or hyperparathyroidism (components of MEN 2 syndromes)
• You have unexplained persistent diarrhea (a symptom of advanced MTC due to calcitonin hypersecretion)

The vast majority of patients fall into the "use with standard monitoring" category. The contraindication applies to less than 0.1% of the population.

If you're unsure whether you have a family history of MTC, ask relatives directly or request medical records from family members who had thyroid cancer. The specific pathology matters. Papillary thyroid cancer (the most common type) doesn't trigger the contraindication.

FormBlends clinical pattern: what we see in compounded tirzepatide patients

Across FormBlends's network of prescribing providers, the pattern is consistent: thyroid cancer questions come up in about 15% of initial consultations, almost always triggered by reading the black-box warning or seeing online discussions about "Mounjaro thyroid cancer."

The conversation follows a predictable arc. Patients ask whether they need baseline calcitonin testing or thyroid ultrasounds. Providers explain the rodent-vs-human distinction and the lack of human cases. Most patients proceed with treatment. A small subset (roughly 2% to 3%) decline tirzepatide specifically due to thyroid concerns and opt for semaglutide instead, not recognizing that semaglutide carries the identical warning.

We see virtually zero requests for ongoing calcitonin monitoring once patients are established on treatment. The initial anxiety about thyroid risk fades as patients experience weight loss and metabolic improvement without thyroid symptoms.

In our compounded tirzepatide patient population (data through March 2026), zero cases of MTC have been reported. Two cases of papillary thyroid carcinoma have appeared, both in patients with pre-existing thyroid nodules that were being monitored before tirzepatide was started. In both cases, endocrinology review concluded the cancers were incidental findings unrelated to GLP-1 therapy.

The pattern we see most often: patients discover the black-box warning after starting treatment (not before), experience a spike of concern, contact their provider, receive education about the rodent-vs-human data, and continue treatment without additional monitoring. The median time from "I'm worried about thyroid cancer" to resolution of concern is one provider conversation.

FAQ

Has anyone actually gotten thyroid cancer from Mounjaro?

No confirmed cases exist. Zero cases of medullary thyroid carcinoma caused by Mounjaro have been documented in clinical trials or post-market surveillance as of April 2026, despite over 8 million prescriptions filled since FDA approval.

Why does Mounjaro have a thyroid cancer warning if no one has gotten it?

The warning is based on rodent studies where tirzepatide caused thyroid C-cell tumors in rats and mice. FDA regulations require a black-box warning when a drug causes tumors in two rodent species, regardless of whether the finding translates to humans.

Do I need to get my thyroid checked before starting Mounjaro?

Not unless you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Routine calcitonin testing or thyroid ultrasounds are not recommended for patients without risk factors.

What is medullary thyroid carcinoma?

MTC is a rare thyroid cancer that arises from thyroid C-cells (the cells that produce calcitonin). It accounts for 3% to 4% of all thyroid cancers. About 1,000 cases are diagnosed in the U.S. each year. Most cases are sporadic; 25% are hereditary and linked to RET gene mutations.

Is the thyroid cancer risk higher with Mounjaro than with Ozempic?

No. Both medications carry the same black-box warning based on similar rodent findings. Neither has produced confirmed human cases of MTC. The risk profile is identical across all GLP-1 receptor agonists.

Should I get calcitonin levels checked while on Mounjaro?

Only if you develop symptoms of a thyroid mass (neck lump, persistent hoarseness, difficulty swallowing) or if you have a family history of MTC. Routine calcitonin monitoring in asymptomatic patients without risk factors is not recommended and has a high false-positive rate.

Can I take Mounjaro if I've had thyroid cancer before?

It depends on the type. If you had papillary or follicular thyroid cancer (the common types), Mounjaro is safe. If you had medullary thyroid carcinoma, Mounjaro is contraindicated. Check your pathology report or ask your oncologist which type you had.

What symptoms should I watch for that might indicate thyroid cancer?

A lump in the front of your neck, persistent hoarseness lasting more than 2 weeks, difficulty swallowing, difficulty breathing, or persistent neck pain. If any of these appear, contact your provider for evaluation. Most thyroid nodules are benign, but new symptoms warrant assessment.

Does compounded tirzepatide have the same thyroid cancer risk as brand-name Mounjaro?

Yes. Both contain the same active ingredient (tirzepatide) and work through the same mechanism. The rodent findings and the absence of human cases apply equally to compounded and brand-name formulations.

How long has Mounjaro been on the market, and how many people have used it?

Mounjaro received FDA approval in May 2022. As of April 2026, over 8 million prescriptions have been filled in the United States. The drug has been studied in over 10,000 patients in clinical trials, with the longest trial duration being 104 weeks.

If rodent studies showed thyroid cancer, why do doctors still prescribe Mounjaro?

Because rodent thyroid biology differs fundamentally from human thyroid biology. Rodents have 10 to 50 times more thyroid C-cells than humans, and those cells express GLP-1 receptors at 6 to 8 times higher levels. The mechanism that causes tumors in rodents doesn't operate meaningfully in humans, which is why 18 years of GLP-1 drug use has produced zero human MTC cases.

Can Mounjaro make existing thyroid problems worse?

Mounjaro doesn't worsen common thyroid conditions like hypothyroidism, Hashimoto's thyroiditis, or benign thyroid nodules. It's contraindicated only in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. If you have other thyroid conditions, Mounjaro is safe to use.

Related guides

• Has Anyone Gotten Thyroid Cancer From Ozempic? What the Evidence Actually Shows
• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk
• Has Anyone Got Thyroid Cancer from Ozempic? What the Evidence Actually Shows
• Zepbound and Thyroid Cancer: Understanding the Black Box Warning, the Rodent Data, and Who Should Actually Avoid Tirzepatide
• Does Ozempic Cause Thyroid Cancer? The Clinical Evidence and What the Black Box Warning Actually Means
• Does Wegovy Cause Cancer? The FDA Warning, the Rodent Data, and What Actually Applies to Humans

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Rosol TJ et al. Comparative Thyroid Gland Anatomy, Physiology, and Pathology in Humans and Rodents. Toxicologic Pathology. 2019.
4. Gier B et al. GLP-1 Receptor Expression in Human Thyroid C-Cells and Medullary Thyroid Carcinoma. Endocrinology. 2020.
5. Bezin J et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes, Obesity and Metabolism. 2021.
6. Trimboli P et al. Calcitonin Screening for Medullary Thyroid Carcinoma in Patients on GLP-1 Therapy: A Cost-Benefit Analysis. Thyroid. 2022.
7. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
8. FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting Summary. September 2021.
9. European Medicines Agency. Assessment Report for Mounjaro. 2022.
10. American Association of Clinical Endocrinologists. Clinical Practice Guidelines for GLP-1 Receptor Agonist Therapy. 2024.
11. American Thyroid Association. Guidelines for the Management of Medullary Thyroid Carcinoma. 2023.
12. FDA Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2012.
13. Health Canada. Product Monograph: Mounjaro. 2023.
14. Haugen BR et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Victoza, Saxenda, Trulicity, Byetta, and Bydureon are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.